As of June 19, 2025, Kiwa Bio-Tech Products Group Corp (KWBT) reports a Net Margin of -16.55%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Kiwa Bio-Tech Products Group Corp's Net Margin
Over recent years, Kiwa Bio-Tech Products Group Corp's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2019-12-31 | -16.55% |
| 2018-12-31 | 1.12% |
| 2017-12-31 | 30.74% |
| 2016-12-31 | 9.26% |
| 2015-12-31 | -2533.33% |
This fluctuation highlights how Kiwa Bio-Tech Products Group Corp manages its overall profitability and cost control over time.
Comparing Kiwa Bio-Tech Products Group Corp's Net Margin to Peers
To better understand Kiwa Bio-Tech Products Group Corp's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Kiwa Bio-Tech Products Group Corp (KWBT) | -16.55% |
| La Jolla Pharmaceutical Co (LJPC) | 25.96% |
| Covalon Technologies Ltd (COV.V) | 8.57% |
| Minerva Neurosciences Inc (NERV) | 4.71% |
| Globeimmune Inc (GBIM) | -42.85% |
| Lattice Biologics Ltd (LBL.V) | -60.16% |
Compared to its competitors, Kiwa Bio-Tech Products Group Corp's Net Margin is among the highest compared to peers, suggesting strong overall cost management and pricing power.